Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

por Zhou, Dongchu, Dong, Xinrui, Zhou, Zhen, Liu, Qiao
Publicado 2023

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

por Zhou, Dongchu, Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Wan, Xiaomin, Tan, Chongqing, Liu, Qiao
Publicado 2022